As of 2025-09-18, the EV/EBITDA ratio of Ligand Pharmaceuticals Inc (LGND) is -31,121.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LGND's latest enterprise value is 3,174.39 mil USD. LGND's TTM EBITDA according to its financial statements is -0.10 mil USD. Dividing these 2 quantities gives us the above LGND EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 11.8x | 9.1x |
| Forward P/E multiples | 10.4x - 16.4x | 12.3x |
| Fair Price | 3.40 - 3.39 | 3.40 |
| Upside | -97.9% - -98.0% | -97.9% |
| Date | EV/EBITDA |
| 2025-09-11 | -31,438.54 |
| 2025-09-10 | -31,229.09 |
| 2025-09-09 | -31,120.52 |
| 2025-09-08 | -31,207.95 |
| 2025-09-05 | -31,378.97 |
| 2025-09-04 | -31,569.21 |
| 2025-09-03 | -31,338.62 |
| 2025-09-02 | -30,798.66 |
| 2025-08-29 | -30,410.50 |
| 2025-08-28 | -30,074.23 |
| 2025-08-27 | -29,908.97 |
| 2025-08-26 | -30,035.79 |
| 2025-08-25 | -29,849.40 |
| 2025-08-22 | -29,905.13 |
| 2025-08-21 | -29,565.01 |
| 2025-08-20 | -29,169.17 |
| 2025-08-19 | -28,942.42 |
| 2025-08-18 | -28,785.81 |
| 2025-08-15 | -28,367.87 |
| 2025-08-14 | -28,888.62 |
| 2025-08-13 | -29,314.25 |
| 2025-08-12 | -28,677.25 |
| 2025-08-11 | -27,585.79 |
| 2025-08-08 | -28,171.87 |
| 2025-08-07 | -27,453.21 |
| 2025-08-06 | -26,699.95 |
| 2025-08-05 | -25,306.81 |
| 2025-08-04 | -25,352.93 |
| 2025-08-01 | -24,839.87 |
| 2025-07-31 | -24,620.81 |
| 2025-07-30 | -25,322.19 |
| 2025-07-29 | -24,620.81 |
| 2025-07-28 | -25,262.62 |
| 2025-07-25 | -25,437.48 |
| 2025-07-24 | -24,861.01 |
| 2025-07-23 | -25,510.50 |
| 2025-07-22 | -24,789.91 |
| 2025-07-21 | -26,453.99 |
| 2025-07-18 | -26,065.83 |
| 2025-07-17 | -25,771.83 |
| 2025-07-16 | -24,246.11 |
| 2025-07-15 | -23,221.91 |
| 2025-07-14 | -23,725.36 |
| 2025-07-11 | -22,722.30 |
| 2025-07-10 | -23,352.58 |
| 2025-07-09 | -22,856.81 |
| 2025-07-08 | -21,457.91 |
| 2025-07-07 | -21,196.58 |
| 2025-07-03 | -21,354.15 |
| 2025-07-02 | -21,177.36 |